Alvotech faces FDA setback for its Simponi biosimilar AVT05
Alvotech’s inflammation-targeting biosimilar AVT05 has been rejected by the U.S. Food and Drug Administration (FDA) because of issues with the…
All articles by Jam Bensilum
Jam Bensilum
Jam Bensilum is a healthcare and pharmaceutical reporter. She has a background in medical communications with extensive experience across both medical affairs and publications. She holds an MSc in Molecular Medicine from Imperial College London and has interests in oncology, infectious disease, biologics, mental health and women’s health.
-
-
Sensei to ditch its lead candidate and cut workforce amidst strategic review
Sensei Biotherapeutics is set to abandon its sole clinical-stage asset solnerstotug as it prepares to cut its workforce and consider…
-
Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a…
-
Excellergy eyes IgE therapy space as Xolair nears patent expiry
After bursting on the scene with a $70m Series A fundraise, Excellergy is forecasting first-in-human trials for both its lead…
-
Galapagos to shutter cell and gene therapy unit
Galapagos NV is winding down its cell and gene therapy (CGT) division after an unsuccessful attempt to sell the unit,…
-
Harmony’s cannabidiol drug flops in pivotal Fragile X Syndrome trial
Harmony Biosciences’ transdermal cannabidiol ZYN002 suffered a setback as a Phase III trial failed to meet the primary endpoint in…
-
Roche bids to broaden MS pipeline and strengthen Ocrevus influence
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton…
-
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Imunon’s IL-12 gene therapy IMNN-001 converts the tumour microenvironment from “cold” to “hot” by both, halting immunosuppressive makers, and stimulating…